The intricate interplay between chronic metabolic conditions and the development of cancer has long been a subject of intense scientific scrutiny. For decades, researchers have observed a robust correlation between Type 2 Diabetes Mellitus (T2DM) and an elevated propensity for various malignancies. While managing elevated blood glucose levels and mitigating obesity are undeniably crucial for individuals living with diabetes, a burgeoning area of scientific inquiry is now meticulously examining whether the pharmacological agents employed in diabetes management themselves exert direct influences on oncogenesis and tumor progression, extending beyond their primary metabolic effects. These investigations are revealing surprising molecular pathways and signaling cascades, potentially opening new avenues for both cancer prevention and adjunctive therapeutic strategies.
The established link between T2DM and certain cancers — including but not limited to hepatic, colorectal, and breast cancers — is multifaceted, stemming from several pathophysiological mechanisms inherent to the diabetic state. Chronic hyperglycemia, a hallmark of uncontrolled diabetes, can fuel cancer cell proliferation and metabolism. Concurrently, hyperinsulinemia, often a consequence of insulin resistance in T2DM, acts as a potent growth factor, stimulating cellular division and inhibiting apoptosis (programmed cell death) through activation of the insulin-like growth factor-1 (IGF-1) pathway, which plays a critical role in tumor growth. Furthermore, the persistent low-grade systemic inflammation characteristic of diabetes contributes to a pro-tumorigenic microenvironment, promoting DNA damage and cellular proliferation. Adiposity, frequently co-occurring with T2DM, adds another layer of complexity, as adipose tissue secretes various adipokines and cytokines that can foster cancer development. Given this complex web of interactions, it became imperative for the scientific community to explore whether the very treatments designed to counteract these diabetic conditions might inadvertently or intentionally impact cancer biology.
A significant stride in this evolving understanding comes from a comprehensive review recently published on December 10, 2025, in the esteemed journal Precision Clinical Medicine. This seminal work, spearheaded by a dedicated team of researchers at Peking University People’s Hospital, transcends the conventional focus solely on glycemic and weight control. Instead, it meticulously synthesizes current research elucidating how widely prescribed antidiabetic medications, such as metformin, SGLT2 inhibitors, and GLP-1 receptor agonists, might modulate cancer progression through a diverse array of biological mechanisms. The insights gleaned from this review substantially enrich the ongoing dialogue regarding the profound and often unexpected ways in which diabetes therapies can influence oncological outcomes, offering a fresh perspective on their potential dual utility.
Among the various antidiabetic agents, metformin, a biguanide derivative and one of the most venerable and extensively prescribed drugs for T2DM globally, stands out for its well-documented pleiotropic effects. The review highlights metformin’s intricate involvement in modulating several key cellular pathways critical for cancer cell survival and proliferation. One of its primary actions involves the activation of AMP-activated protein kinase (AMPK), a cellular energy sensor that, when activated, suppresses anabolic processes like cell growth and proliferation, effectively putting the brakes on runaway cellular division. This activation subsequently leads to the inhibition of the mammalian target of rapamycin (mTOR) pathway, a central regulator of cell growth, protein synthesis, and metabolism, which is often hyperactive in many cancers. Furthermore, metformin has been shown to influence the PI3K/AKT pathway, another crucial signaling cascade involved in cell survival, proliferation, and metabolism, which is frequently dysregulated in malignant cells. Beyond these direct cellular effects, metformin also appears to exert an immunomodulatory role, enhancing anti-cancer immune responses by influencing the tumor microenvironment (TME). The TME, a complex ecosystem comprising immune cells, fibroblasts, endothelial cells, and extracellular matrix, can either support or hinder tumor growth. Metformin’s ability to create a less hospitable environment for tumor cells, partly through its impact on immune surveillance and inflammatory pathways, underscores its multifaceted therapeutic potential. Clinical observations, particularly in retrospective analyses, have suggested that metformin use is associated with a reduced incidence and improved prognosis in certain cancer types, notably colorectal and liver cancers, although its precise role in other malignancies, such as breast cancer, remains an area requiring further clarification through prospective studies.
The newer classes of antidiabetic medications, SGLT2 inhibitors (sodium-glucose co-transporter 2 inhibitors) and GLP-1 receptor agonists (glucagon-like peptide-1 receptor agonists), are also demonstrating intriguing effects beyond their primary glucose-lowering mechanisms. SGLT2 inhibitors, which promote glucose excretion via the kidneys, lead to reduced systemic glucose availability, a factor that could starve rapidly proliferating cancer cells. Emerging evidence suggests these agents may also possess anti-inflammatory properties and directly induce apoptosis in various cancer cell lines, thereby limiting tumor growth. GLP-1 receptor agonists, known for their effects on insulin secretion, glucagon suppression, and gastric emptying, also contribute to significant weight loss, a factor that indirectly reduces cancer risk. Moreover, preclinical studies indicate that GLP-1 RAs may directly influence cancer cell growth, reduce chronic inflammation, and enhance programmed cell death, similar to SGLT2 inhibitors. However, the review prudently emphasizes that the impact of these newer drugs is not uniformly consistent across all cancer types or specific medications within each class. The nuanced differences in their mechanisms of action and cellular targets necessitate careful, individualized assessment and further dedicated research to fully characterize their oncological implications.
The complexities inherent in these investigations mean that a definitive, blanket statement about the cancer-modulating effects of antidiabetic drugs is currently elusive. Dr. Linong Ji, a distinguished researcher prominently involved in this burgeoning field, underscored this very point, stating, "While antidiabetic medications are indispensable in the management of diabetes, their broader influences on cancer remain an area of profound ongoing exploration. This extensive review illuminates the intricate molecular mechanisms through which these pharmacological agents may influence the trajectory of cancer. Nevertheless, the existing evidence presents a mixed picture, necessitating sustained and rigorous investigation into the long-term impacts of these crucial medications on cancer patients. Furthermore, we must diligently explore the potential for developing highly targeted cancer therapies based on these evolving discoveries." This expert perspective highlights the scientific community’s cautious optimism and commitment to unraveling the precise conditions and patient populations that might benefit most from these indirect oncological effects.
The cumulative findings from this review underscore the growing imperative for a more personalized approach to medicine, particularly for individuals afflicted with both diabetes and cancer. A refined understanding of how specific antidiabetic compounds interact with diverse cancer pathologies could empower clinicians to tailor therapeutic regimens more effectively. This could translate into optimized prevention strategies for diabetic patients at high risk of cancer, as well as improved outcomes for those battling both diseases simultaneously. The current insights also provide a compelling rationale for conducting future prospective clinical trials, designed not only to confirm these preclinical and observational findings but also to explore the potential repurposing of existing diabetes medications for use as adjunctive cancer therapies, either alone or in synergistic combination with standard oncological treatments. Moreover, the broader public health implications are substantial. For populations facing a heightened prevalence of both diabetes and cancer, understanding the oncological effects of these widely used medications could inform public health initiatives aimed at mitigating cancer risk and improving overall patient well-being.
In conclusion, the emerging evidence suggesting that medications primarily prescribed for diabetes exert profound influences on cancer biology represents a significant paradigm shift in both endocrinology and oncology. This fascinating intersection promises to redefine our understanding of chronic disease management, potentially unlocking novel therapeutic strategies and fostering a more integrated approach to patient care. The journey towards fully elucidating these complex interactions is ongoing, fueled by dedicated research and collaboration across scientific disciplines, with the ultimate goal of enhancing patient lives.
This transformative work was made possible through the generous support of several key funding bodies, including the 2024 National Clinical Key Specialty Construction Program of China (Department of Endocrinology, Peking University People’s Hospital) with allocation from the central government budget. Additional crucial support was provided by the Noncommunicable Chronic Diseases National Science and Technology Major Project (grant Nos. 2023ZD0508200, 2023ZD0508205), the Clinical Medicine Plus X Young Scholars Project of Peking University (grant No. PKU2025PKULCXQ025), and the Fundamental Research Funds for the Central Universities.
About the Author
